AU766748B2 - The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder - Google Patents

The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder Download PDF

Info

Publication number
AU766748B2
AU766748B2 AU55432/00A AU5543200A AU766748B2 AU 766748 B2 AU766748 B2 AU 766748B2 AU 55432/00 A AU55432/00 A AU 55432/00A AU 5543200 A AU5543200 A AU 5543200A AU 766748 B2 AU766748 B2 AU 766748B2
Authority
AU
Australia
Prior art keywords
mph
treatment
dose
saline
methylphenidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU55432/00A
Other languages
English (en)
Other versions
AU5543200A (en
Inventor
Elizabeth Janina Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Publication of AU5543200A publication Critical patent/AU5543200A/en
Application granted granted Critical
Publication of AU766748B2 publication Critical patent/AU766748B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU55432/00A 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder Ceased AU766748B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9913458.7A GB9913458D0 (en) 1999-06-09 1999-06-09 The therapeutic use of d-threo-methylphenidate
GB9913458 1999-06-09
PCT/GB2000/002234 WO2000074680A1 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder

Publications (2)

Publication Number Publication Date
AU5543200A AU5543200A (en) 2000-12-28
AU766748B2 true AU766748B2 (en) 2003-10-23

Family

ID=10855048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55432/00A Ceased AU766748B2 (en) 1999-06-09 2000-06-08 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder

Country Status (9)

Country Link
EP (1) EP1185268B1 (enExample)
JP (1) JP2003501387A (enExample)
AT (1) ATE302006T1 (enExample)
AU (1) AU766748B2 (enExample)
CA (1) CA2376215A1 (enExample)
DE (1) DE60022033T2 (enExample)
ES (1) ES2243273T3 (enExample)
GB (1) GB9913458D0 (enExample)
WO (1) WO2000074680A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR101318806B1 (ko) 2005-01-20 2013-10-16 인스티튜트 포 몰리큘러 메디신, 인코포레이티드 메틸페니데이트 유도체 및 그 용도
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
CN108348775B (zh) 2015-09-15 2021-07-02 普瑞西斯生物学研究有限责任公司 芬坎法明的前药

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003673A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Sustained-release formulation of d-threo-methylphenidate
WO1999016439A1 (en) * 1997-09-29 1999-04-08 Celgene Corporation CHRONIC, BOLUS ADMINISTRATION OF D-threo METHYLPHENIDATE
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
MX9805870A (enExample) * 1996-01-22 1999-01-31
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003673A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Sustained-release formulation of d-threo-methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
WO1999016439A1 (en) * 1997-09-29 1999-04-08 Celgene Corporation CHRONIC, BOLUS ADMINISTRATION OF D-threo METHYLPHENIDATE

Also Published As

Publication number Publication date
ES2243273T3 (es) 2005-12-01
WO2000074680A1 (en) 2000-12-14
EP1185268A1 (en) 2002-03-13
CA2376215A1 (en) 2000-12-14
ATE302006T1 (de) 2005-09-15
DE60022033D1 (de) 2005-09-22
AU5543200A (en) 2000-12-28
DE60022033T2 (de) 2006-03-30
EP1185268B1 (en) 2005-08-17
GB9913458D0 (en) 1999-08-11
JP2003501387A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
Gatley et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans
van Lemmen et al. Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest
Burns et al. DARK classics in chemical neuroscience: fentanyl
Drobes et al. Effects of naltrexone and nalmefene on subjective response to alcohol among non‐treatment‐seeking alcoholics and social drinkers
JP5203373B2 (ja) 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト
EP1617832B1 (en) Compositions for affecting weight loss
Glowa et al. Effects of dopamine reuptake inhibitors on food-and cocaine-maintained responding: II. Comparisons with other drugs and repeated administrations.
US11045465B2 (en) Methods and compositions to prevent addiction
Lile et al. The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics
Doggrell et al. Treatment of dementia with neurotransmission modulation
Wiley et al. Nicotine-like discriminative stimulus effects of bupropion in rats.
AU766748B2 (en) The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
Tolliver et al. Comparison of cocaine and GBR 12935: effects of locomotor activity and stereotypy in two inbred mouse strains
Witkin et al. Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine
Steinpreis et al. Methadone produces conditioned place preference in the rat
Li et al. Place conditioning and locomotor effects of N-substituted, 4′, 4′′-difluorobenztropine analogs in rats
Platt et al. Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms
WO2021174116A1 (en) Methods for opiate and opioid overdose prevention and reversal
Platt et al. Opioid receptors and the discriminative stimulus effects of ethanol in squirrel monkeys: Mu and delta opioid receptor mechanisms
Snyder et al. Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders
Naguy et al. Newly FDA-approved psychotropic medications
Zapata et al. Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan
Witkin et al. Toxicity: Mechanisms and Pharmacotherapy
Canfield Pharmacokinetic and pharmacodynamic characterization of illicitly manufactured fentanyls
MXPA06012348A (es) Metodos para atenuar el potencial de co-abuso.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)